Literature DB >> 32291245

Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy.

Philip Q Ding1, Atul Batra2, Yuan Xu3, Geoffrey P McKinnon4, Winson Y Cheung2.   

Abstract

BACKGROUND: Even though obesity is a well-established risk factor for developing colon cancer, its prognostic value is not very well understood. The present study elucidated the effect of obesity, as measured by the body mass index (BMI) and body surface area (BSA), on colon cancer outcomes. PATIENTS AND METHODS: Patients with a diagnosis of stage III colon cancer from 2011 to 2016 who had undergone adjuvant chemotherapy in Alberta, Canada were identified. The demographic variables, treatment characteristics, and survival data were collected from the electronic medical records. Obesity was defined using the BMI in accordance with the World Health Organization criteria, and BSA was categorized as ≤ 2.0 m2 (low) and > 2.0 m2 (high). The effect of BMI and BSA on 5-year cancer-specific survival (CSS) and overall survival (OS) was analyzed using univariate and multivariate analysis.
RESULTS: A total of 915 patients were identified with a median age of 64 years. Of these, 37% were overweight or obese, and the BSA was high in 42% of the patients. The survival outcomes for the obese and underweight patients were not significantly different from those with a normal BMI (P = .61 and P = .30 for OS and CSS, respectively). Similarly, no correlation was found between BSA and OS or CSS. Although 21% of patients experienced a > 10-week delay in receiving adjuvant chemotherapy, neither BMI nor BSA correlated significantly with chemotherapy timing (P = .45).
CONCLUSIONS: Our results suggest that BMI and BSA do not correlate with survival outcomes in patients with stage III colon cancer. The role of a healthy lifestyle in an improved colon cancer prognosis might not be driven by its effects on obesity.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Body mass index; Body surface area; Chemotherapy timing; Medical oncology; Survival

Year:  2020        PMID: 32291245     DOI: 10.1016/j.clcc.2020.02.010

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  2 in total

1.  Association of Body Mass Index with Survival in Asian Patients with Colorectal Cancer.

Authors:  Sangwon Lee; Dong Hee Lee; Jae-Hoon Lee; Su-Jin Shin; Hye Sun Lee; Eun Jung Park; Seung Hyuk Baik; Kang Young Lee; Jeonghyun Kang
Journal:  Cancer Res Treat       Date:  2021-10-15       Impact factor: 5.036

2.  Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.

Authors:  Brandon N VanderVeen; Thomas D Cardaci; Sierra J McDonald; Sarah S Madero; Christian A Unger; Brooke M Bullard; Reilly T Enos; Kandy T Velázquez; Jason L Kubinak; Daping Fan; E Angela Murphy
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.